Jill DeSimone - 01 Mar 2023 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Director
Signature
/s/ Mark A. Meltz, attorney in fact
Issuer symbol
N/A
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 16:54:27 UTC
Previous filing
05 Jan 2023
Next filing
14 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 01 Mar 2023 Common Stock 50,000 $5.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant.